StockData
Boston Scientific Corp logo

Boston Scientific Corp (BSX) stock

BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3053% below fair value
$43.64+0.61 (+1.42%)

Close on Nov 18, 2026Market cap $63.24BP/E 17.7Yield –

Boston Scientific free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Boston Scientific's free cash flow for the twelve months ending Jun 30, 2026 was $3.63B, up 4.0% year over year. For fiscal 2025 it was $3.66B, up 38.3% from the year before. Over ten years it grew 23.5% a year on average. The highest annual figure on record is $3.66B in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.66B+38.3%
FY2024Dec 31, 2024$2.65B+47.6%
FY2023Dec 31, 2023$1.79B+91.0%
FY2022Dec 31, 2022$938.00M-28.7%
FY2021Dec 31, 2021$1.32B+16.3%
FY2020Dec 31, 2020$1.13B-17.7%
FY2019Dec 31, 2019$1.38B–
FY2018Dec 31, 2018-$6.00M-100.5%
FY2017Dec 31, 2017$1.11B+37.3%
FY2016Dec 31, 2016$806.00M+81.5%
FY2015Dec 31, 2015$444.00M-56.0%
FY2014Dec 31, 2014$1.01B+16.8%
FY2013Dec 31, 2013$865.00M-17.9%
FY2012Dec 31, 2012$1.05B+49.7%
FY2011Dec 31, 2011$704.00M+1228.3%
FY2010Dec 31, 2010$53.00M-89.9%
FY2009Dec 31, 2009$523.00M-38.8%
FY2008Dec 31, 2008$854.00M+49.6%
FY2007Dec 31, 2007$571.00M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.28B+13.3%
Q1 FY2026Mar 31, 2026$171.00M-51.7%
Q4 FY2025Dec 31, 2025$1.01B-14.1%
Q3 FY2025Sep 30, 2025$1.16B+41.2%
Q2 FY2025Jun 30, 2025$1.13B+71.6%
Q1 FY2025Mar 31, 2025$354.00M–
Q4 FY2024Dec 31, 2024$1.18B+70.9%
Q3 FY2024Sep 30, 2024$823.00M+62.0%
Q2 FY2024Jun 30, 2024$658.00M+27.8%
Q1 FY2024Mar 31, 2024-$15.00M-119.0%
Q4 FY2023Dec 31, 2023$690.00M+16.0%
Q3 FY2023Sep 30, 2023$508.00M+58.7%
Q2 FY2023Jun 30, 2023$515.00M+155.0%
Q1 FY2023Mar 31, 2023$79.00M–
Q4 FY2022Dec 31, 2022$595.00M+180.7%
Q3 FY2022Sep 30, 2022$320.00M-10.6%
Q2 FY2022Jun 30, 2022$202.00M-62.4%
Q1 FY2022Mar 31, 2022-$179.00M-185.6%
Q4 FY2021Dec 31, 2021$212.00M-58.8%
Q3 FY2021Sep 30, 2021$358.00M-39.7%
Q2 FY2021Jun 30, 2021$537.00M+167.2%
Q1 FY2021Mar 31, 2021$209.00M–
Q4 FY2020Dec 31, 2020$514.00M+1.6%
Q3 FY2020Sep 30, 2020$594.00M+55.9%
Q2 FY2020Jun 30, 2020$201.00M0.0%
Q1 FY2020Mar 31, 2020-$177.00M-161.7%
Q4 FY2019Dec 31, 2019$506.00M–
Q3 FY2019Sep 30, 2019$381.00M-10.4%
Q2 FY2019Jun 30, 2019$201.00M–
Q1 FY2019Mar 31, 2019$287.00M+115.8%
Q4 FY2018Dec 31, 2018-$87.00M-114.4%
Q3 FY2018Sep 30, 2018$425.00M+8.4%
Q2 FY2018Jun 30, 2018-$477.00M-308.3%
Q1 FY2018Mar 31, 2018$133.00M–
Q4 FY2017Dec 31, 2017$605.00M+18.9%
Q3 FY2017Sep 30, 2017$392.00M–
Q2 FY2017Jun 30, 2017$229.00M–
Q1 FY2017Mar 31, 2017-$119.00M–
Q4 FY2016Dec 31, 2016$509.00M–
Q3 FY2016Sep 30, 2016-$102.00M–

More Boston Scientific figures

See a number that looks wrong?